Ruibing Wang received his B.S. degree in chemistry from Jilin University (Changchun, China) in 2002 and his Ph.D. degree in organic chemistry from Queen's University (Kingston, ON, Canada) in 2007. Due to the excellence of his Ph.D. research, his thesis was entitled the Outstanding Thesis Award by Queen’s School of Graduate Studies. He continued in the same laboratory as a Postdoctoral Fellow at Queen's University (2007-2008) and then moved to the Steacie Institute for Molecular Sciences at the National Research Council of Canada as a Research Associate for about two years, where he worked on nanomaterial development and studied their applications in solar cell and bioimaging. In late 2009, he became a Senior R&D Scientist in the field of nuclear medicine, medical devices, and radiopharmaceutical development at Nordion Inc., a world-leading radiopharmaceutical firm based in Ottawa, ON, Canada. At Nordion, he worked as the Technical Design Authority Chemist for GSK’s Bexxar product (a radiolabeled antibody nanomedicine for non-Hodgkin’s lymphoma diagnostics and therapy) and recently has been assigned as the Technical Design Authority Chemist for TheraSphere (a Y-90 glass microspheres product for liver cancer treatment). Since July 2013, Dr. Wang has joined BTG plc together with the Targeted Therapies Division of Nordion. Since joining BTG plc, his research and development activities have been mainly focused on the research and development of novel medical devices (such as microparticles and nanomedicine) and interventional medicine for cancer diagnostics and therapeutics, and these may include supramolecular formulation and nanoformulation or microparticle formulation of active drug components and/or therapeutic isotopes for targeted delivery and controlled drug release.
Biography Updated on 19 October 2013